Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 09 February 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Certolizumab pegol concentrations are associated with endoscopic outcomes in Crohn's

A study in the latest issue of the Clinical Gastroenterology & Hepatology evaluates the association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease.

News image

Monitoring plasma concentrations of anti–tumor necrosis factor agents could optimize treatment of patients with Crohn's disease.

In a post hoc analysis of data from a clinical trial, Dr Jean–Frédéric Colombel and colleagues compared the relationship between plasma concentrations of certolizumab pegol and endoscopic and clinical responses and remission with certolizumab pegol therapy in patients with moderate to severe ileocolonic Crohn's disease.

The research team analyzed data from the Endoscopic Mucosal Improvement in Patients with Active Crohn's Disease Treated with certolizumab pegol trial, from 89 adult patients with active endoscopic Crohn's disease.

Patients received subcutaneous certolizumab pegol (400 mg) at weeks 0, 2, and 4 and then every 4 weeks until week 52.

Higher concentrations of certolizumab pegol at week 8 were associated with endoscopic response
Clinical Gastroenterology & Hepatology

Endoscopic evaluations were performed at weeks 0, 10, and 54.

The research team found that blood samples were collected to measure certolizumab pegol plasma concentrations at weeks 8 and 54.

Certolizumab pegol quartiles at weeks 8 and 54 were correlated with endoscopic response and remission at weeks 10 and 54, respectively.

The team noted that higher concentrations of certolizumab pegol at week 8 were associated with endoscopic response, and remission at week 10.

At week 54, the research team found that rates of endoscopic remission correlated with plasma concentrations of certolizumab pegol.

There was a significant inverse relationship between plasma concentrations of certolizumab pegol, and baseline levels of C-reactive protein and body weight.

Dr Colombel's team concludes, "Endoscopic response and remission are associated with higher plasma concentrations of certolizumab pegol in patients with moderate to severe ileocolonic Crohn's disease."

"These results support the need to consider the pharmacokinetics of anti–tumor necrosis factor agents and therapeutic drug monitoring to optimize treatment."

Clin Gastroenterol Hepatol 2014: 12(3): 423-431.e1
26 February 2014

Go to top of page Email this page Email this page to a colleague

 09 February 2016 
Cancer-specific prognosis in octogenarians with colorectal cancer
 09 February 2016 
Eosinophilic esophagitis and parental allergies
 09 February 2016 
Bowel preparation for colonoscopy screening
 08 February 2016 
Immunity in the human gut
 08 February 2016 
Cancelled colonoscopy appointments
 08 February 2016 
Cognitive function in Crohn's disease
 05 February 2016 
Helicobacter cinaedi bacteremia
 05 February 2016 
Methotrexate and remission in ulcerative colitis
 05 February 2016 
Treatment for ileal pouch-anal anastomosis for Crohn’s colitis
 04 February 2016 
Diabetes and liver cancer
 04 February 2016 
Colorectal cancer screening
 04 February 2016 
H. pylori and coronary heart disease 
 03 February 2016 
Acute diverticulitis and IBS 
 03 February 2016 
Microbiota of the colonic mucosa and chronic constipation
 03 February 2016 
Guidelines for chronic pancreatitis
 02 February 2016 
Ramosetron and IBS-diarrhea
 02 February 2016 
IBD emergency department visits
 02 February 2016 
Probiotics for H. pylori management
 01 February 2016 
Depressive symptoms in IBD 
 01 February 2016 
Obesity and hepatocellular carcinoma risk
 01 February 2016 
Managing HBV in pregnancy
 29 January 2016 
Colorectal cancer after colonoscopy
 29 January 2016 
Acute diverticulitis in immunosuppressed patients
 29 January 2016 
Vitamin D and colorectal cancer risk
 28 January 2016 
Tissue anti-TNF drug levels and IBD
 28 January 2016 
First line treatment of H. pylori infection
 28 January 2016 
Tetracycline for rosacea increases the risk of IBD
 27 January 2016 
Steroids in children with Crohn's
 27 January 2016 
Self-management IBS program 
 27 January 2016 
Human gut microbiome in IBD 
 26 January 2016 
Smoking and symptomatic diverticular disease
 26 January 2016 
Step-down therapy in PPI-responsive esophageal eosinophilia 
 26 January 2016 
Diet and IBD risk
 25 January 2016 
IBD monitoring using smartphones
 25 January 2016 
Self-management IBS program
 25 January 2016 
Colorectal cancer after a negative screening sigmoidoscopy
 22 January 2016 
Length of Barrett's and cancer
 22 January 2016 
Psychosocial interventions and alcohol abstinence in chronic liver disease
 22 January 2016 
Helicobacter pylori antibiotic resistance
 21 January 2016 
Increasing adenoma detection rate during colonoscope withdrawal
 21 January 2016 
Microscopic colitis current concepts
 21 January 2016 
Statins as a management strategy for constipation 
 20 January 2016 
Health status after bariatric surgery
 20 January 2016 
Hep E infection in West Africa
 20 January 2016 
Preventing endoscopic bacterial transmission
 19 January 2016 
PPIs and phlebotomy in hereditary hemochromatosis
 19 January 2016 
Predicting liver cirrhosis in Hep C
 19 January 2016 
Frozen vs fresh fecal microbiota transplantation
 18 January 2016 
Hospitalization for diverticulitis in the USA
 18 January 2016 
H. pylori and gastric cancer across Europe
 18 January 2016 
Enteral nutrition in children with Crohn's
 15 January 2016 
Alcohol- and HCV-related hepatocellular carcinoma
 15 January 2016 
Recurrent colonic diverticulitis
 15 January 2016 
Colonic diverticula and colorectal cancer risk
 14 January 2016 
Risk stratification of incidentally discovered gallstones
 14 January 2016 
Treatment of refractory cholestatic pruritus
 14 January 2016 
Colonic diverticula and colorectal cancer risk 
 13 January 2016 
C-section delivery and IBD risk
 13 January 2016 
Primary biliary cholangitis treatment with incomplete UDCA response
 13 January 2016 
Colon cancer screening rates 

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us